InMed reports positive long-term preclinical AD study results for INM-901 confirming prior pilot data

InMed Pharmaceuticals Inc.

Long-term (7-month) in vivo study confirms cognitive and memory improvements seen in 3-month pilot using 5xFAD amyloidosis model.
INM-901-treated AD groups achieved statistical significance in certain behavioral assessments vs. placebo.
Clear dose response observed across Novel Object Recognition, Open Field, Barnes Maze, and other tests.
Additional molecular analyses (receptor engagement, neuroinflammation, neurogenesis, neuroprotection) are ongoing.
CMC/GLP studies being planned to support IND submission; INM-901 targets CB1/CB2/PPAR pathways and penetrates BBB.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.